• Safi Bello

GSK’s asthma biologic hits quality of life goal

Pharma Times ----- GlaxoSmithKline has presented new data showing that its asthma drug Nucala “significantly improves” quality of life and lung function in patients with a severe, eosinophilic form of the condition. The Phase IIIb MUSCA study successfully met all its primary and secondary endpoints, showing that when the first-in-class biologic was added to standard of care, patients experienced clinically and statistically significant improvements in their health-related quality of life and lung function compared to those treated with placebo and standard of care. To learn more click on the picture below to read the article.

GSK’s asthma biologic hits quality of life goal - Read More from Pharma Times

1 view
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon